As the U.S. market experiences a mix of record highs and tempered expectations due to recent inflation reports, investors are closely monitoring economic indicators that could influence Federal ...

ACADIA Pharmaceuticals Inc. ( NASDAQ:ACAD ) recently released a strong earnings report, and the market responded ...

Acadia Pharmaceuticals ACAD reported second-quarter 2025 earnings of 16 cents per share, which beat the Zacks Consensus ...

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that Doug Williamson, M.D., Executive Vice President, Head of Research and Development, wil ...

Recursion Pharmaceuticals RXRX, a TechBio company that decodes biology and chemistry to industrialize drug discovery, is ...

Explore ACADIA Pharmaceuticals' Q2 2025 earnings highlights, featuring strong revenue growth, DAYBUE expansion, NUPLAZID guidance raise, and robust ...

Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) shares are trading higher Wednesday after the company won summary judgement in a patent suit regarding its Nuplazid drug. What To Know: ...

In the assessment of 12-month price targets, analysts unveil insights for ACADIA Pharmaceuticals, presenting an average target of $33.37, a high estimate of $42.00, and a low estimate of $19.00.

Revenue Growth: ACADIA Pharmaceuticals's remarkable performance in 3 months is evident. As of 31 March, 2024, the company achieved an impressive revenue growth rate of 73.75%.

Oppenheimer analyst Jay Olson maintained a Hold rating on ACADIA Pharmaceuticals (ACAD – Research Report) today and set a price target of $17.00. The company’s shares closed yesterday at $15.72.

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate at two upcoming investor conferences: Citi's 2024 Global Healthcar ...

Acadia Pharmaceuticals (NASDAQ: ACAD) jumped 32% after winning summary judgement in a patent suit regarding its drug Nuplazid, which is used to treat Parkinson's disease.